Volume 11, Issue 9 (12-2013)
IJRM 2013, 11(9): 753-0 |
Back to browse issues page
Fatemeh Bazarganipour1 
, Saeide Ziaei * 2, Ali Montazeri3 , Fatemeh Foroozanfard4 , Soghrat Faghihzadeh5
, Saeide Ziaei * 2, Ali Montazeri3 , Fatemeh Foroozanfard4 , Soghrat Faghihzadeh5
1- Department of Reproductive Health and Midwifery, Faculty of Medical Science, Tarbiat Modares University, Tehran, Iran
2- Department of Reproductive Health and Midwifery, Faculty of Medical Science, Tarbiat Modares University, Tehran, Iran ,ziaei_sa@modares.ac.ir
3- Mental Health Research Group, Health Metrics Research Center, Iranian Institute for Health Sciences Research, ACECR, Tehran, Iran
4- Department of Obstetrics and Gynecology, Kashan University of Medical Sciences, Kashan, Iran
5- Faculty of Medical Sciences, Zanjan University of Medical Sciences, Zanjan, Iran
2- Department of Reproductive Health and Midwifery, Faculty of Medical Science, Tarbiat Modares University, Tehran, Iran ,
3- Mental Health Research Group, Health Metrics Research Center, Iranian Institute for Health Sciences Research, ACECR, Tehran, Iran
4- Department of Obstetrics and Gynecology, Kashan University of Medical Sciences, Kashan, Iran
5- Faculty of Medical Sciences, Zanjan University of Medical Sciences, Zanjan, Iran
Abstract: (2510 Views)
Background: A preliminary report indicated that the Iranian version of modified polycystic ovary syndrome health-related quality of life questionnaire (MPCOSQ) is a valid measure of health-related quality of life (HRQOL) in PCOS patients. Accordingly, the Iranian version of MPCOSQ was subjected to further psychometric analyses among a different sample of patients with PCOS.
Objective: To examine discriminant and convergent validity of the Iranian version of MPCOSQ.
Materials and Methods: This was a cross sectional study of 200 women with PCOS that was carried out in two private gynecology clinics in Kashan, Iran. Discriminant validity was assessed using the known groups comparison. Convergent validity was evaluated by assessing the correlation between similar content on the MPCOSQ and the SF-36.
Results: The mean scores for the MPCOSQ showed that women rated lowest on the infertility and menstrual subscales indicating worst health in these dimensions. The results from the SF-36 questionnaire indicated that emotional and vitality domains were the areas of poorest health. Known groups comparison showed that the MPCOSQ differentiated well between sub-groups of women who differed in PCOS specific symptoms, lending support to its discriminant validity. Convergent validity was assessed and as expected a good positive correlation was found between related subscales of the two instruments.
Conclusion: The MPCOSQ has now been extensively tested in Iran and can be considered for using as an outcome measure in future outcome studies in this population.
Objective: To examine discriminant and convergent validity of the Iranian version of MPCOSQ.
Materials and Methods: This was a cross sectional study of 200 women with PCOS that was carried out in two private gynecology clinics in Kashan, Iran. Discriminant validity was assessed using the known groups comparison. Convergent validity was evaluated by assessing the correlation between similar content on the MPCOSQ and the SF-36.
Results: The mean scores for the MPCOSQ showed that women rated lowest on the infertility and menstrual subscales indicating worst health in these dimensions. The results from the SF-36 questionnaire indicated that emotional and vitality domains were the areas of poorest health. Known groups comparison showed that the MPCOSQ differentiated well between sub-groups of women who differed in PCOS specific symptoms, lending support to its discriminant validity. Convergent validity was assessed and as expected a good positive correlation was found between related subscales of the two instruments.
Conclusion: The MPCOSQ has now been extensively tested in Iran and can be considered for using as an outcome measure in future outcome studies in this population.
Type of Study: Original Article |
References
1. Hahn S, Janssen OE, Tan S, Pleger K, Mann K, chedlowski M, et al. Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome. Euro J Endocrinol 2005; 153: 853-860. [DOI:10.1530/eje.1.02024]
2. Cronin L, Guyatt G, Griffith L, Wong E, Azziz R, Futterweit W, et al. Development of a health-related quality-of-life questionnaire (PCOSQ) for women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 1998; 83: 1976-1987.
3. Guyatt G, Weaver B, Cronin L, Dooley JA, Azziz R. Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated. J Clin Epidemiol 2004; 57: 1279-1287. [DOI:10.1016/j.jclinepi.2003.10.018]
4. Jones GL, Benes K, Clark TL, Denham R, Holder MG, Haynes TJ, et al. The polycystic ovary syndrome health-related quality of life questionnaire (PCOSQ): a validation. Hum Reprod 2004; 19: 371-377. [DOI:10.1093/humrep/deh048]
5. McCook J, Reame N, Thatcher S. Health-related quality of life issues in women with polycystic ovary syndrome. J Obstet Gynecol Neonatal Nurs 2005; 34: 12-20. [DOI:10.1177/0884217504272945]
6. Barnard L, Ferriday D, Guenther N, Strauss B, Balen AH, Dye L. Quality of life and psychological well being in polycystic ovary syndrome. Hum Reprod 2007; 22: 2279-2286. [DOI:10.1093/humrep/dem108]
7. Bazarganipour F, Ziaei S, Montazeri A, Faghihzadeh S, Frozanfard F. Psychometric properties of the Iranian version of modified Polycystic Ovary Syndrome Health-Related Quality of Life Questionnaire. Hum Reprod 2012; 27: 2729-2736. [DOI:10.1093/humrep/des199]
8. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-47. [DOI:10.1093/humrep/deh098]
9. Montazeri A, Goshtasebi A, Vahdaninia M, Gandek B. The Short Form Health Survey (SF-36): translation and validation study of the Iranian version. Qual Life Res 2005; 14: 875-882. [DOI:10.1007/s11136-004-1014-5]
10. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21: 1440-1447. [DOI:10.1210/jcem-21-11-1440]
11. Lever WF, Schaumburg-Lever G. Acne vulgaris. Histopatbology of the Skin. 7th Ed. Philadelphia: JB Lippincott; 1990:218-9
12. Donyavi T, Naieni KH, Nedjat S, Vahdaninia M, Najafi M, Montazeri A. Socioeconomic status and mortality after acute myocardial infarction: a study from Iran. Int J Equity Health 2011; 10: 9. [DOI:10.1186/1475-9276-10-9]
13. Kaasa S, Bjordal K, Aaronson N, Moum T, Wist E, Hagen S, et al. The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy. Eur J Cancer 1995; 31: 2260-2263. [DOI:10.1016/0959-8049(95)00296-0]
14. Bazarganipour F, Ziaei S, Montazeri A, Frozanfard F, Faghihzadeh S. Health-related quality of life and its relationship with clinical symptoms among Iranian patients with polycystic ovarian syndrome. Iran J Reprod Med 2013; 11: 371-378.
15. Ching HL, Burke V, Stuckey BG. Quality of life and psychological morbidity in women with polycystic ovary syndrome: body mass index, age and the provision of patient information are significant modifiers. Clin Endocrinol (Oxf) 2007; 66: 373-379. [DOI:10.1111/j.1365-2265.2007.02742.x]
16. SooHoo NF, McDonald AP, Seiler JG, McGillivary GR. Evaluation of the construct validity of the DASH questionnaire by correlation to the SF-36. J Hand Surg Am 2002; 27: 537-541. [DOI:10.1053/jhsu.2002.32964]
17. Coffey S, Bano G, Mason H. Health-related quality of life in women with polycystic ovary syndrome: a comparison with the general population using the polycystic ovary syndrome questionnaire (PCOSQ) and the Short Form-36 (SF-36). Gynecol Endocrinol 2006; 22: 80-86. [DOI:10.1080/09513590600604541]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |